阿帕替尼联合紫杉醇和顺铂方案治疗非小细胞肺癌的疗效分析

Efficacy Analysis of Apatinib Combined with Paclitaxel and Cisplatin in the Treatment of Non-Small Cell Lung Cancer

目的 探讨阿帕替尼联合紫杉醇和顺铂方案治疗非小细胞肺癌(NSCLC)的疗效分析。方法 选取2018年3月—2021年7月就诊于该院的NSCLC患者92例,按照随机数表法分为研究组47例和对照组45例。对照组采取紫杉醇和顺铂方案化疗,研究组采取阿帕替尼联合紫杉醇和顺铂方案治疗,比较两组疾病控制率、治疗前后肿瘤标志物[血清血管内皮生长因子(VEGF)、癌胚抗原(CEA)、细胞角蛋白19片段(Cyfra21-1)]水平、生存质量[卡氏评分(KPS)]。结果 研究组疾病控制率为85.11%高于对照组66.67%,差异有统计学意义(χ^(2)=4.296,P<0.05)。治疗3个周期后,研究组血清VEGF、CEA、Cyfra21-1水平均低于对照组,差异有统计学意义(P<0.05)。治疗3个周期后,研究组生存质量有效率93.62%高于对照组75.56%,差异有统计学意义(χ^(2)=5.813,P<0.05)。不良反应发生率组间比较,差异无统计学意义(χ^(2)=0.379,P>0.05)。结论阿帕替尼联合紫杉醇和顺铂方案协同治疗NSCLC,能有效控制疾病进展,降低肿瘤标志物水平,未增加患者不良反应,提高患者生存质量。

Objective To investigate the efficacy of apatinib combined with paclitaxel and cisplatin in the treatment of non-small cell lung cancer(NSCLC). Methods A total of 92 patients with NSCLC who were treated in the hospital from March 2018 to July2021 were selected and divided into a study group of 47 cases and a control group of 45 cases according to the random number table method. The control group was treated with paclitaxel and cisplatin chemotherapy, and the study group was treated with apatinib combined with paclitaxel and cisplatin. The disease control rate, tumor marker levels [serum vascular endothelial growth factor(VEGF), carcinoembryonic antigen(CEA), cytokeratin 19 fragment(Cyfra21-1)], and quality of life [karl’s score(KPS)] were compared between the two groups before and after treatment. Results The disease control rate of the study group was 85.11% higher than that of the control group 66.67%,the difference was statistically significant(χ^(2)=4.296, P<0.05). After 3cycles of treatment, the serum levels of VEGF, CEA and Cyfra21-1 in the study group were lower than those in the control group, the difference was statistically significant(P<0.05). After 3 cycles of treatment, the effective rate of quality of life in the study group was 93.62% higher than that in the control group 75.56%, the difference was statistically significant(χ^(2)=5.813, P<0.05). There was no significant difference in the incidence of adverse reactions between groups(χ^(2)=0.379, P>0.05). Conclusion Apatinib combined with paclitaxel and cisplatin in the synergistic treatment of NSCLC can effectively control disease progres-sion, reduce the level of tumor markers, without increasing the adverse reactions of patients, and improve the quality of life of patients.